Walvax Biotechnology Co., Ltd.
沃森生物
300142
Shenzhen Stock Exchange
Company Profile
1. Two Global blockbuster products Walvax owns the products for 13-valent Pneumococcal Conjugate Vaccine and Human Papillomavirus Vaccine. In addition, Walvax has quadrivalent Meningococcal Conjugate Vaccine in the R&D pipeline. 2. Industry-leading R&D platform and capacity Walvax has established advanced research and development technology platforms for human vaccines and owns plenty of state-level qualifications, such as National High-tech Enterprise, National Certified Enterprise Technology Center, etc. Additionally, Walvax has over 71 patents that have been granted in China and foreign countries. 3. High standard and stringent manufacturing and quality management system as well as globally advanced commercialization capability Walvax has established a manufacturing site with annual production capacity of 170 million doses at full load for vaccines including Haemophilus influenzae type b conjugate vaccine in vial and prefilled presentation, 13-valent Pneumococcal Conjugate Vaccine in vial and prefilled presentation, Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine in vial and prefilled presentation, 23-valent Pneumococcal polysaccharide vaccine in vial and prefilled presentation, lyophilized Group A and C meningococcal polysaccharide conjugate vaccine in vial and prefilled presentation, Group ACYW135 meningococcal polysaccharide vaccine in vial and prefilled presentation, lyophilized Group A and C meningococcal polysaccharide vaccine and adsorbed DTaP vaccine. 4. Top-notch core team and professional training mechanism Walvax has over 200 employees with Master's or PhD degrees.
Full description
Established in 2001, Walvax Biotechnology Co., Ltd. (“Walvax”) is a fast-growing group company mainly engaged in research, development, manufacturing and distribution of biopharmaceutical products with a leading position in the Chinese industry for innovative human vaccines. Walvax has established a rich product pipeline for vaccines, including the products for 13-valent Pneumococcal Conjugate Vaccine and Human Papillomavirus Vaccine. Meanwhile, Walvax has constructed industry-leading R&D and commercialization technology platforms and assembled a talented technology and management team. In addition, Walvax has cooperated closely with international organizations, such as WHO, UNICEF, GAVI, etc. in the global public health area. Currently, products manufactured and marketed by Walvax are for the prevention of severe infectious diseases, including Haemophilus influenzae type b conjugate vaccine in vial and prefilled presentation, 13-valent Pneumococcal Conjugate Vaccine in vial and prefilled presentation, Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine in vial and prefilled presentation, 23-valent Pneumococcal polysaccharide vaccine in vial and prefilled presentation, lyophilized Group A and C meningococcal polysaccharide conjugate vaccine in vial and prefilled presentation, Group ACYW135 meningococcal polysaccharide vaccine in vial and prefilled presentation, lyophilized Group A and C meningococcal polysaccharide vaccine and adsorbed DTaP vaccine. Walvax’s largest state-of-the-art manufacturing base is located in the High-tech Industry Development Zone of Yuxi Municipality in China’s southwestern province of Yunnan. Walvax strives to build this manufacturing base to make international quality biopharmaceutical products for the Chinese and global markets.